US/China-based MicuRx Gets $55m Series C Funding For MRX-I Antibiotic

Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $55 million in a Series C venture capital round to fund further clinical trials in the US for its next-generation oral oxazolidinone MRX-I through to the drug’s first New Drug Application filing in China.